We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, IQVIA Holdings (IQV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.81 per share, reflecting an increase of 12.9% compared to the same period last year. Revenues are forecasted to be $3.85 billion, representing a year-over-year increase of 3.1%.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some IQVIA metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenues- Technology & Analytics Solutions' to reach $1.49 billion. The estimate suggests a change of +3.8% year over year.
The consensus estimate for 'Revenues- Research & Development Solution' stands at $2.19 billion. The estimate indicates a year-over-year change of +3.2%.
Analysts expect 'Revenues- Contract Sales & Medical Solutions' to come in at $176.87 million. The estimate points to a change of -3.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Backlog' will likely reach $31.31 billion. The estimate compares to the year-ago value of $28.8 billion.
Analysts predict that the 'Segment Profit- Technology & Analytics Solution' will reach $364.08 million. The estimate compares to the year-ago value of $355 million.
It is projected by analysts that the 'Segment Profit- Contract Sales & Medical Solutions' will reach $19.06 million. The estimate compares to the year-ago value of $12 million.
Analysts' assessment points toward 'Segment Profit- Research & Development Solutions' reaching $517.57 million. The estimate is in contrast to the year-ago figure of $495 million.
IQVIA shares have witnessed a change of -8.6% in the past month, in contrast to the Zacks S&P 500 composite's +2% move. With a Zacks Rank #3 (Hold), IQV is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to IQVIA (IQV) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, IQVIA Holdings (IQV - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.81 per share, reflecting an increase of 12.9% compared to the same period last year. Revenues are forecasted to be $3.85 billion, representing a year-over-year increase of 3.1%.
The consensus EPS estimate for the quarter has been revised 0.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some IQVIA metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenues- Technology & Analytics Solutions' to reach $1.49 billion. The estimate suggests a change of +3.8% year over year.
The consensus estimate for 'Revenues- Research & Development Solution' stands at $2.19 billion. The estimate indicates a year-over-year change of +3.2%.
Analysts expect 'Revenues- Contract Sales & Medical Solutions' to come in at $176.87 million. The estimate points to a change of -3.4% from the year-ago quarter.
The combined assessment of analysts suggests that 'Backlog' will likely reach $31.31 billion. The estimate compares to the year-ago value of $28.8 billion.
Analysts predict that the 'Segment Profit- Technology & Analytics Solution' will reach $364.08 million. The estimate compares to the year-ago value of $355 million.
It is projected by analysts that the 'Segment Profit- Contract Sales & Medical Solutions' will reach $19.06 million. The estimate compares to the year-ago value of $12 million.
Analysts' assessment points toward 'Segment Profit- Research & Development Solutions' reaching $517.57 million. The estimate is in contrast to the year-ago figure of $495 million.
View all Key Company Metrics for IQVIA here>>>
IQVIA shares have witnessed a change of -8.6% in the past month, in contrast to the Zacks S&P 500 composite's +2% move. With a Zacks Rank #3 (Hold), IQV is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>